A pilot study of buspirone in the treatment of social phobia
1991; Elsevier BV; Volume: 5; Issue: 1 Linguagem: Inglês
10.1016/0887-6185(91)90019-p
ISSN1873-7897
AutoresDennis J. Munjack, Jerry R. Bruns, Patricia L. Baltazar, Richard A. Brown, Michelle T. Leonard, Robert Nagy, Ralph J. Koek, Benjamin Crocker, Stuart Schafer,
Tópico(s)Mental Health Research Topics
ResumoSeventeen patients who met DSM-III-R criteria for social phobia were seen in an eight week open trial of buspirone. Eleven subjects completed the study, having taken an average of 48 mg per day of medication by the end of week 8. Rating scales of generalized anxiety, social anxiety, depression, and disability were administered. Preliminary findings indicated that 1) buspirone is an effective anxiolytic for anxiety in general, and 2) generalized social phobia symptoms partially responded to buspirone, although few patients responded dramatically. The limitations of this study and some problems with the assessment instruments are discussed. Recommendations for future studies are offered.
Referência(s)